Lenalidomide Glenmark

Lenalidomide, the active ingredient in Lenalidomide Glenmark, is an immunomodulatory agent presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves disease control and prolongs progression‑free survival in relapsed or refractory patients. Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory mantle cell lymphoma.

Common Side Effects: - Fatigue or weakness. - Nausea, vomiting or loss of appetite. - Diarrhoea or constipation. - Rash or mild skin irritation. - Decreased neutrophil count (neutropenia). - Low platelet count (thrombocytopenia).

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia or infections requiring hospitalization. - Secondary primary malignancies. - Hepatotoxicity with elevated liver enzymes. - Severe skin reactions including Stevens‑Johnson syndrome. - Cardiac arrhythmias or heart failure exacerbation.

Lenalidomide requires careful monitoring and specific safety measures.

Pregnancy: contraindicated (Category X); avoid use in pregnant women and ensure effective contraception. Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia. Renal impairment: use with caution and monitor renal function closely. Drug interactions: review concomitant medications for potential CYP or immunosuppressive effects. Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Lenalidomide may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants: increased risk of thrombosis when combined without prophylaxis. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Immunosuppressants: may enhance overall immunosuppression. - Nephrotoxic agents: monitor renal function closely. - Hormonal contraceptives: reduced efficacy; advise alternative contraception methods.